https://www.selleckchem.com/pr....oducts/pemigatinib-i
In vitro, RvD1 also represses LPS-induced inflammation in RAW264.7 cells. These effects may be mainly attributed to RvD1 markedly suppressing excessive inflammatory responses via the inhibition of the TLR4-MyD88-mediated NF-κB and MAPK signalling pathways as well as enhancing antioxidation capacity via the activation of the Nrf2 pathway. These results demonstrate that RvD1 is a promising hepatoprotective agent for the therapy of NASH. These results demonstrate that RvD1 is a promising hepatoprotective agent for the therap
Like
Comment
Share
